Business
Notice of Results
Notice of Results.
About this update from Verici Dx Plc
[{"type":"text","content":"\n\n\n\n\nVerici Dx plc\n(\"Verici Dx\" or the \"Company\")\n \nNotice of Results\n \nVerici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that it will report its final results for the year ended 31 December 2022 on Monday 5 June 2023.\n \nThe data read-out from the extended Clarava™ trial remains on track to be announced by the end of June, in line with previous guidance. An investor briefing covering the FY22 financial results together with an update on the Company's products will be scheduled at this stage.\n \nEnquiries:\n \n\n\n\n\nVerici Dx\n\n\nwww.vericidx.com\n\n\n\n\nSara Barrington, CEO\n\n\nVia Walbrook PR\n\n\n\n\nJulian Baines, Chairman\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\n\n\nTel: +44 20 7496 3000\n\n\n\n\nAubrey Powell / Sam Butcher\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR Limited\n\n\nTel: +44 20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus / Stephanie Cuthbert /\nSam Allen\n\n\nMob: +44 7980 541 893 / +44 7796 794 663 /\n07502 558 258\n\n\n\n\n \nAbout Verici Dx plc www.vericidx.com\nVerici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.\n \nThe foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.\n \nVerici Dx's two lead products are Clarava™, a pre-transplant prognosis test for the risk of early acute rejection, and Tutivia™, a post-transplant test focused upon acute cellular rej...